Psoriasis is a multifactorial immuno-inflammatory
skin disease, characterized by keratinocyte hyperproliferation and aberrant immune activation. Although the pathogenesis is complex, the interactions among
inflammation, Th17-mediated immune activation, and keratinocyte
hyperplasia are considered to play a crucial role in the occurrence and development of
psoriasis. Therefore, pharmacological interventions on the "
inflammation-Th17-keratinocyte" vicious cycle may be a potential strategy for
psoriasis treatment. In this study,
JPH203 (a specific inhibitor of LAT1, which engulfs
leucine to activate mTOR signaling)-loaded, ultraviolet B (UVB) radiation-induced, keratinocyte-derived extracellular vesicles (J@EV) were prepared for
psoriasis therapy. The EVs led to increased
interleukin 1 receptor antagonist (IL-1RA) content due to UVB irradiation, therefore not only acting as a carrier for
JPH203 but also functioning through inhibiting the IL-1-mediated
inflammation cascade. J@EV effectively restrained the proliferation of inflamed keratinocytes via suppressing mTOR-signaling and NF-κB pathway in vitro. In an
imiquimod-induced psoriatic model, J@EV significantly ameliorated the related symptoms as well as suppressed the over-activated immune reaction, evidenced by the decreased keratinocyte
hyperplasia, Th17 expansion, and IL17 release. This study shows that J@EV exerts therapeutic efficacy for
psoriasis by suppressing LAT1-mTOR involved keratinocyte hyperproliferation and Th17 expansion, as well as inhibiting IL-1-NF-κB mediated
inflammation, representing a novel and promising strategy for
psoriasis therapy.